Targeting the interaction of HDAC2 and MYC in Group 3 medulloblastoma
J Ecker, I Oehme, F Selt, M Kool, M Schnölzer, U Warnken, S Brabetz, R Wechsler-Reya, AE Kulozik, SM Pfister, O Witt, T Milde · Klinische Pädiatrie · 2016 · Heft 11
Bibliografische Angaben
Zusammenfassung
Patients with high-risk subgroup medulloblastoma (MB) show poor overall survival rates despite aggressive treatment while survivors suffer from important treatment-associated morbidity. Particularly poor outcome is observed in patients with tumors of the molecular subgroup Group 3 with an amplification and high levels of the transcription factor MYC. We have previously shown that Group 3 MB cell lines with MYC amplification are highly susceptible to pan- and class I-histone deacetylase (HDAC) inhibitor treatment. We here explore the molecular interaction of the well known oncogenic driver MYC and class I HDAC2.…
